Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 22:15:380.
doi: 10.1186/s12906-015-0825-y.

Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model

Affiliations

Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model

Su Kang Kim et al. BMC Complement Altern Med. .

Abstract

Background: Benign prostatic hyperplasia (BPH) is one of the common male diseases, which is provoked by dihydrotestosterone (DHT) and androgen signals. Several studies showed that curcumin has various effects of prevention and treatment to diseases. We investigated whether curcumin may repress the development of BPH in male Wistar rats.

Methods: Seven weeks male Wistar rats were and divided into 4 groups (normal group, BPH group, finasteride group, curcumin group; n = 8 for each group). In order to induce BPH in rats, rats were castrated and testosterone was injected subcutaneously everyday (s.c., 20 mg/kg). Rats in the curcumin group were treated 50 mg/kg, administered orally for 4 weeks. After 4 weeks, all rats were sacrificed and their prostate and serum were analyzed.

Results: Compared to the finasteride group as positive group, the curcumin group showed similarly protective effect on BPH in histopathologic morphology, prostate volume. Results of immunohistochemistry and western-blot showed decreased expressions of VEGF, TGF-ß1, and IGF1 were also decreased in the curcumin group.

Conclusions: These results suggested that curcumin inhibited the development of BPH and might a useful herbal treatment or functional food for BPH.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
H&E stains of prostate tissue in each group (× 100 and × 400). Arrowheads indicate interacina fibrosis in ventral lobe of prostate tissue. # P < 0.05 compared with the normal group; * P < 0.05 compared with the BPH group
Fig. 2
Fig. 2
The expressions of vascular endothelial growth factor A(VEGF), transforming growth factor, beta 1(TGF-ß1), and insulin-like growth factor 1(IGF1) by immunohistochemistry in each group (× 100). # P < 0.05 compared with the normal group; * P < 0.05 compared with the BPH group
Fig. 3
Fig. 3
The expressions of vascular endothelial growth factor A(VEGF), transforming growth factor, beta 1(TGF-ß1), and insulin-like growth factor 1(IGF1) by western-blot in each group. # P < 0.05 compared with the normal group; * P < 0.05 compared with the BPH group

Comment in

References

    1. Lee YJ, Jeong SJ, Byun SS, Lee JJ, Han JW, Kim KW. Prevalence and correlates of nocturia in community-dwelling older men: results from the korean longitudinal study on health and aging. Korean J Urol. 2012;53(4):263–7. doi: 10.4111/kju.2012.53.4.263. - DOI - PMC - PubMed
    1. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol. 2008;40(3):649–56. doi: 10.1007/s11255-008-9333-z. - DOI - PubMed
    1. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009;1155:43–56. doi: 10.1111/j.1749-6632.2009.04115.x. - DOI - PubMed
    1. Carson C, 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4 Suppl 1):2–7. doi: 10.1016/S0090-4295(03)00045-1. - DOI - PubMed
    1. Uygur MC, Gur E, Arik AI, Altug U, Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia. 1998;30(1):5–10. doi: 10.1111/j.1439-0272.1998.tb01375.x. - DOI - PubMed

Publication types

MeSH terms